Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal versus intravenous methylprednisolone for acute thoracolumbar spinal cord injury
IRCT20190116042374N1Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Oct 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methylprednisolone in acute traumatic thoracolumbar spinal cord injury (TLSCI) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Sensory signs and Symptoms of gastrointestinal tract infection. Started Oct 2018; status: completed.
02
Drugs
methylprednisolone
03
Conditions
acute traumatic thoracolumbar spinal cord injury (TLSCI)
Beyond the preview
Go deeper on IRCT20190116042374N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190116042374N1.